Serpatinib after resistance to platinib

Platinib and serpatinib are two targeted drugs targeting RET gene fusions or mutations, and they play an important role in cancer treatment. However, long-term use of platinib may lead to drug resistance, which is a common problem faced by many targeted drugs. When resistance to platinib develops, serpatinib becomes a viable treatment option.

Platinib, as a targeted inhibitor of receptor tyrosine kinaseRET, can selectively inhibit the spread and metastasis of cancer cells to distant sites. However, due to individual differences and the long-term use of drugs, some patients will develop drug resistance after using them for a period of time. This is usually due to a genetic mutation in the cancer cells that prevents drugs from effectively inhibiting their growth.

Selpatinib has become a treatment option that has attracted much attention after resistance to platinib. Serpatinib is also a highly selective RET oral inhibitor with significant efficacy in cancer patients with RET gene fusions or mutations. Serpatinib has a different chemical structure and mechanism of action than platinib, and therefore may still be effective against cancer cells that have become resistant to platinib.

Before taking serpatinib, patients should undergo comprehensive genetic testing and disease evaluation. This can help determine whether RET gene fusions or mutations are present and assess the suitability and potential efficacy of serpatinib. Additionally, close communication and collaboration with your doctor is key to ensuring successful treatment.

However, it is worth noting that although serpatinib provides new treatment opportunities for drug-resistant patients, not all drug-resistant patients will respond to serpatinib. Therefore, during use, the patient's reaction and condition changes should be paid close attention to, and the treatment plan should be adjusted in a timely manner.

References:

https://www.sciencedirect.com/science/article/pii/S0923753420431278